We are live on ! Find out more
ARRY

Array Biopharma Inc
ARRY

Delisted

ARRY was delisted on the 29th of July, 2019.

Back to rankings

134 hedge funds and large institutions have $651M invested in Array Biopharma Inc in 2013 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 43 increasing their positions, 41 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

53% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 15

45% more capital invested

Capital invested by funds: $447M → $651M (+$203M)

5% more funds holding

Funds holding: 128 → 134 (+6)

5% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 41

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

93% less call options, than puts

Call options by funds: $79K | Put options by funds: $1.08M

Holders
134
Holders Change
+6
Holders Change %
+4.69%
% of All Funds
4.35%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.13%
New
23
Increased
43
Reduced
41
Closed
15
Calls
$79K
Puts
$1.08M
Net Calls
-$997K
Net Calls Change
-$584K

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$15.1M
2
PA
Pinnacle Associates
New York
+$13.8M
3
BA
BlackRock Advisors
Delaware
+$11.4M
4
TCM
TimesSquare Capital Management
New York
+$8.7M
5
State Street
State Street
Massachusetts
+$7.34M

Top Sellers

Rank Fund Capital Flow
1
BI
BVF Inc
California
-$8.39M
2
BIT
BlackRock Institutional Trust
California
-$8M
3
RG
Redmile Group
California
-$6.53M
4
KIA
Kopp Investment Advisors
Minnesota
-$4.63M
5
CIP
Chartwell Investment Partners
Pennsylvania
-$4.52M
Name Holding Trade Value Shares
Change 		Change in
Stake
PI
26
Putnam Investments
Massachusetts
$5.51M -$92K -15,483 -2%
TC
27
TFS Capital
Pennsylvania
$4.43M -$225K -37,869 -5%
Bank of New York Mellon
28
Bank of New York Mellon
New York
$3.8M +$123K +20,641 +3%
Renaissance Technologies
29
Renaissance Technologies
New York
$3.65M +$3.49M +586,752 New
PA
30
Perceptive Advisors
New York
$3.56M +$3.29M +553,550 +2,865%
Invesco
31
Invesco
Georgia
$3.42M +$23.9K +4,025 +0.7%
Millennium Management
32
Millennium Management
New York
$3.3M +$1.84M +309,829 +140%
Geode Capital Management
33
Geode Capital Management
Massachusetts
$3.23M +$248K +41,736 +9%
PCP
34
Perimeter Capital Partners
Georgia
$3.03M -$920K -154,799 -24%
CGT
35
Capital Guardian Trust
California
$2.96M -$149K -25,000 -5%
TCIM
36
TIAA CREF Investment Management
New York
$2.93M -$96.4K -16,232 -3%
State of Wisconsin Investment Board
37
State of Wisconsin Investment Board
Wisconsin
$2.8M – – –
GC
38
Guggenheim Capital
Illinois
$2.67M +$2.55M +428,570 New
CCI
39
Columbus Circle Investors
$2.66M +$2.54M +427,651 New
NI
40
Numeric Investors
Massachusetts
$2.62M -$900K -151,499 -26%
BG
41
BlackRock Group
United Kingdom
$2.58M +$2.45M +413,100 +19,046%
Wells Fargo
42
Wells Fargo
California
$2.5M +$1.48M +248,484 +163%
Goldman Sachs
43
Goldman Sachs
New York
$2.41M -$1.15M -193,671 -33%
SCM
44
Suffolk Capital Management
New York
$2.3M +$59.4K +10,000 +3%
BIM
45
BlackRock Investment Management
Delaware
$2.06M +$121K +20,313 +7%
California Public Employees Retirement System
46
California Public Employees Retirement System
California
$2.06M +$220K +37,100 +13%
TD Asset Management
47
TD Asset Management
Ontario, Canada
$2.04M +$612K +103,100 +46%
OAM
48
Oxford Asset Management
United Kingdom
$1.89M -$1.39M -233,528 -44%
PAM
49
Panagora Asset Management
Massachusetts
$1.85M -$288K -48,541 -14%
Charles Schwab
50
Charles Schwab
California
$1.75M -$6.4K -1,078 -0.4%
1
2
3 4 5

ARRY Hedge Fund Activity: Q3 2013 in Review

134 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma Inc (ARRY) for Q3 2013, worth a combined $651M — up 45% from $447M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new ARRY positions and 15 closed out — a net gain of 8 holders — while 43 added to existing stakes and 41 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $15.1M. The largest seller was BVF Inc, cutting an estimated $8.39M.

  • 134 institutional investors held Array Biopharma Inc (ARRY) as of Q3 2013, up from 128 in Q2 2013.
  • Funds reported $651M of Array Biopharma Inc stock for Q3 2013, up 45% quarter-over-quarter.
  • 23 funds opened new Array Biopharma Inc positions in Q3 2013 and 15 closed out, a net change of +8 holders.
  • The largest Array Biopharma Inc buyer in Q3 2013 was T. Rowe Price Associates, an estimated $15.1M added.
  • The largest Array Biopharma Inc seller in Q3 2013 was BVF Inc, an estimated $8.39M sold.

Based on aggregated 13F filings for Q3 2013.